Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 3
1983 2
1984 4
1985 3
1986 5
1987 4
1988 5
1989 6
1990 3
1991 2
1992 2
1993 2
1994 1
1995 2
1996 1
1997 2
1998 1
2000 2
2001 4
2002 4
2003 4
2004 3
2005 5
2006 3
2007 3
2008 3
2009 3
2010 2
2011 3
2012 3
2013 2
2014 1
2015 1
2016 5
2017 2
2018 1
2019 3
2020 3
2021 6
2022 8
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Among authors: risse ml. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Martin T, et al. Among authors: risse ml. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. Blood Cancer J. 2023. PMID: 37156782 Free PMC article. Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Dimopoulos MA, et al. Among authors: risse ml. Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4. Am J Hematol. 2023. PMID: 35604280 Free PMC article. No abstract available.
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Kawano Y, et al. Among authors: risse ml. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e360-e367. doi: 10.1016/j.clml.2023.06.011. Epub 2023 Jul 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37479547 Free article. Clinical Trial.
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
Martin TG, Capra M, Mohty M, Suzuki K, Quach H, Cavo M, Moreau P, Dimopoulos M, Yong K, Tekle C, Foster MC, Barnes Y, Risse ML, Mikhael J. Martin TG, et al. Among authors: risse ml. Transplant Cell Ther. 2023 Feb;29(2):134.e1-134.e7. doi: 10.1016/j.jtct.2022.11.005. Epub 2022 Nov 11. Transplant Cell Ther. 2023. PMID: 36372355 Free article. Clinical Trial.
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Martin T, et al. Among authors: risse ml. Blood Cancer J. 2023 Sep 27;13(1):152. doi: 10.1038/s41408-023-00923-6. Blood Cancer J. 2023. PMID: 37752114 Free PMC article. No abstract available.
[Risks of drug screening using immunoassays].
Schütz H, Verhoff MA, Risse M, Auch J, Weiler G. Schütz H, et al. Among authors: risse m. Dtsch Med Wochenschr. 2004 Sep 10;129(37):1931-4. doi: 10.1055/s-2004-831365. Dtsch Med Wochenschr. 2004. PMID: 15372373 Review. German.
[Deaths in hotels].
Risse M, Weilbächer N, Birngruber C, Verhoff MA. Risse M, et al. Arch Kriminol. 2010 May-Jun;225(5-6):188-94. Arch Kriminol. 2010. PMID: 20642257 German.
124 results